Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth

San Diego, CA, October 9, 2025 — Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a manuscript in Science describing the discovery and preclinical characterization of small molecules that inhibit RAS-dependent PI3Kα oncogenic signaling by specifically blocking the interaction between […] The post Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth appeared first on Vividion Therapeutics .